Murli Krishna Pharma Private Limited

Murli Krishna Pharma Private Limited - pharma in Pune, Maharashtra, India. FY 2026 financials & compliance.
CIN U24230PN2004PTC206917 Incorporated 02 April 2004 ROC Pune HQ Pune, Maharashtra, India
Active Private Limited Company pharma MSME · Medium
Data last updated
Revenue · FY 2025
₹146.68 Cr
▼ 21% YoY
Net profit · FY 2025
₹1.74 Cr
Net margin 1.2%
EBITDA · FY 2025
₹10.33 Cr
EBITDA margin 7%
Authorised capital
₹32.5 Cr
Registered with MCA
Paid-up capital
₹5.39 Cr
Issued & subscribed
Open charges
₹81.98 Cr
Satisfied ₹13.76 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
218
Provident fund records

About Murli Krishna Pharma Private Limited

Data last updated:

Murli Krishna Pharma Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 April 2004 and has been in existence for over 22 years.

The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24230PN2004PTC206917. Its GSTIN is 27AADCM8601K1ZB (Maharashtra).

The company has an authorised share capital of ₹32.5 Cr and a paid-up capital of ₹5.39 Cr. It is led by directors including Satya Ramani Vadlamani (Managing Director) and Venkat Murli Krishna Vadlamani.

Its last annual general meeting (AGM) was held on 31 December 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 98 Ranjangaon MIDC Tal Shirur, Pune, Maharashtra, India – 412209.

As per the financials filed for FY 2025, the company reported a revenue of ₹146.68 Cr, a decline of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.74 Cr (net margin 1.2%) and EBITDA of ₹10.33 Cr (EBITDA margin 7%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 15% over five years.

The company has about 218 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Murli Krishna Pharma. As per MCA filings, the company has open charges of ₹81.98 Cr and satisfied charges of ₹13.76 Cr on record. Court records list 13 cases involving the company, including 5 filed by the company and 8 filed against it; 3 cases are pending. The company has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is Bafna Pharmaceuticals Limited with revenue of ₹148.6 Cr. The company has 5 MSME Form 1 returns on record between 2019 and 2023, listing 840 overdue payments to 26 micro and small suppliers.

Murli Krishna Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0070963). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website murlikrishnapharma.com.

Company details

CIN U24230PN2004PTC206917
Registration Number 206917
Incorporation Date 02 April 2004
ROC Pune
Listing Status Unlisted
Company Status Active
Date of Last AGM 31 December 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0070963

CIN history

Murli Krishna Pharma has one previous CIN (Corporate Identification Number): U24230MH2004PTC145510. The current CIN is U24230PN2004PTC206917, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24230PN2004PTC206917Current
U24230MH2004PTC145510Previous
Key People
Satya Ramani Vadlamani Managing Director Nithyagovind Nominee Director Venkat Murli Krishna Vadlamani Director

Recognitions & Rankings of Murli Krishna Pharma

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-MH-19-0070963

Contact details

Murli Krishna Pharma Private Limited's registered office is in Pune, Maharashtra. Its website is murlikrishnapharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    murlikrishnapharma.com
  • Social Media
  • Registered Address
    D – 98 Ranjangaon MIDC Tal Shirur, Pune, Maharashtra, India – 412209
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Murli Krishna Pharma Private Limited, buy the company report.

Comprehensive company report
Murli Krishna Pharma Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Murli Krishna Pharma operates one associated brand: Murli Krishna Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Murli Krishna Pharma
Formulation intermediate drugs are manufactured by the company.murlikrishnapharma.com

Business activity

The main business activity of Murli Krishna Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Murli Krishna Pharma Private Limited, buy the company report.

Financials of Murli Krishna Pharma Private Limited

FY 2025 filings available

Murli Krishna Pharma Private Limited reported revenue of ₹146.68 Cr (down 21% YoY) for FY 2025.

Revenue · FY 2025
₹146.68 Cr ▼ 21%
Net profit · FY 2025
₹1.74 Cr margin 1.2%
EBITDA · FY 2025
₹10.33 Cr margin 7%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 21%
3 years · compounded
▲ 11%
5 years · compounded
▲ 15%
EBITDA CAGR growth
1 year
▼ 37%
3 years · compounded
▲ 41%

Revenue fell 21% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 15%. EBITDA fell 37% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹146.68 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹10.33 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹1.74 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin7%
Net Profit Margin1.2%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Murli Krishna Pharma Private Limited, buy the company report.

Board of directors of Murli Krishna Pharma Private Limited

Murli Krishna Pharma has 4 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Nithyagovind
Also directs: Indilyfe Sponsor LLP, Fleming Laboratories Limited, Biome Biologicals Private Limited and 4 more
Nominee Director27 May 20206 Years 5 MonthsCurrent
Satya Ramani VadlamaniManaging Director02 Apr 200422 Years 7 MonthsCurrent
Venkat Murli Krishna VadlamaniDirector15 Jul 20242 Years 3 MonthsCurrent
Vijay Shastri KalyanasundaramDirector02 Apr 200422 Years 7 MonthsCurrent
View all directors

Peer comparison

Murli Krishna Pharma Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Bafna Pharmaceuticals Limited₹148.6 Cr (FY 2025)-5.0%Chennai, Tamil Nadu, India
Celon Laboratories Private Limited₹148.17 Cr (FY 2025)-7.0%Hyderabad, Telangana, India
Canton Laboratories Private Limited₹147.08 Cr (FY 2025)26.0%Vadodara, Gujarat, India
Murli Krishna Pharma Private Limitedthis company₹146.68 Cr (FY 2025)₹1.74 Cr1.2%-21.0%218Pune, Maharashtra, India
Raman & Weil Private Limited₹145.87 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Pulse Pharmaceuticals Private Limited₹145.08 Cr (FY 2024)-1.0%Hyderabad, Telangana, India
Goodway Chemicals Private Limited₹144.1 Cr (FY 2025)-12.0%Mumbai, Maharashtra, India

To see the full peer comparison of Murli Krishna Pharma Private Limited, buy the company report.

Auditor

Murli Krishna Pharma Private Limited is audited by M S K A & Associates for the financial year 2025.

Auditor firmFinancial yearFirm registration number
M S K A & AssociatesFY 2025105047W

Shareholding

The shareholding of Murli Krishna Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Murli Krishna Pharma Private Limited, buy the company report.

Charges & borrowings

Open charges
₹81.98 Cr
Satisfied charges
₹13.76 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹60.68 Cr
Others₹20.00 Cr
Axis Bank Limited₹1.30 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
22 Aug 2025101178916Hdfc Bank Limited₹30 LakhOpen
28 Jun 2024100950333Others₹10 CrOpen
28 Jun 2024100950346Others₹10 CrOpen
04 Sep 2023100776388Axis Bank Limited₹1.3 CrOpen
09 May 2023100758146Hdfc Bank Limited₹23.02 LakhOpen

To see the full charge records of Murli Krishna Pharma Private Limited, buy the company report.

Total charge records: 12 View all charges

Deals & funding

Murli Krishna Pharma Private Limited has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023.

Total deals
25
Secondary share transfers
13
Funding rounds
12
Disclosed funding
₹90.38 Cr

Deals on record (5 of 25)

WhenDealAmountParties
Dec 2023Secondary share transferUndisclosedBuyer: 2 individuals
Seller: Murli Krishna Exports Private Limited , an individual
Sep 2023Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Apr 2023Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Mar 2010Funding round₹75.8 LakhInvestors: Krutow International Inc, 3 individuals
Dec 2007Funding round₹44 LakhInvestors: Murli Krishna Exports Private Limited , 3 individuals

To see the full deal history of Murli Krishna Pharma Private Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Murli Krishna Pharma Private Limited has 5 MSME Form 1 returns on record between 2019 and 2023, listing 840 overdue payments to 26 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 26)

SupplierAmount dueDue sinceReported on
Anish Pharmaequip Private Limited
an individual supplier
an individual supplier
an individual supplier
an individual supplier

To see the full MSME payment records of Murli Krishna Pharma Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Murli Krishna Pharma Private Limited has a workforce of 218 employees on its EPFO records as of Sep 26, 2025, across 1 active EPFO establishment.

Employee count
218
Active EPFO establishments
1
Employee growth
9.55%

GST

Murli Krishna Pharma has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AADCM8601K1ZBMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Murli Krishna Pharma Private Limited, buy the company report.

Recent activity

Murli Krishna Pharma Private Limited has 15 board changes on record since 2004: 5 appointments and 10 cessations. The latest: Venkat Murli Krishna Vadlamani ceased to be Additional Director on 02 Dec 2024.

AGM
Murli Krishna Pharma Private Limited last Annual general meeting of members was held on 31 Dec 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.30 Cr with Charge ID 101178916 was registered on 22 Aug 2025.
Filing
Murli Krishna Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune.
Ceased
Venkat Murli Krishna Vadlamani ceased to be Additional Director.
Appointed
Venkat Murli Krishna Vadlamani was appointed as Director.
Charges
A charge with Others amounted to Rs. 10.00 Cr with Charge ID 100950333 was registered on 28 Jun 2024.
Charges
A charge with Others amounted to Rs. 10.00 Cr with Charge ID 100950346 was registered on 28 Jun 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 59.43 Cr registered on 25 Nov 2020 with Charge ID 100403600 was modified on 01 Feb 2024.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.30 Cr with Charge ID 100776388 was registered on 04 Sep 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.23 Cr with Charge ID 100758146 was registered on 09 May 2023.
Ceased
Zainul Fakhruddin Bharmal ceased to be Director.
Charges
A charge registered on 10 Apr 2007 via Charge ID 10048499 with The Bank Of Maharashtra Limited was fully satisfied on 17 Feb 2021.

26 earlier events are in the company report.

News

Frequently asked questions

Murli Krishna Pharma is an active private limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 April 2004 (22+ years old) and is registered under CIN U24230PN2004PTC206917.

Murli Krishna Pharma has 4 current directors:

The latest financial statements of Murli Krishna Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 December 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Murli Krishna Pharma is 27AADCM8601K1ZB, registered in Maharashtra.

The CIN (Corporate Identification Number) of Murli Krishna Pharma is U24230PN2004PTC206917. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Murli Krishna Pharma has 13 court cases on record: 5 filed by the company and 8 filed against it. 3 are pending. Most are in the district courts.

Murli Krishna Pharma was incorporated on 02 April 2004, making it 22+ years old. It is registered with the Registrar of Companies, Pune.

Murli Krishna Pharma has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023.

The peers of Murli Krishna Pharma by revenue are Bafna Pharmaceuticals Limited, Celon Laboratories Private Limited, Canton Laboratories Private Limited, Raman & Weil Private Limited, Pulse Pharmaceuticals Private Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Venkat Murli Krishna Vadlamani ceased to be Additional Director on 02 Dec 2024. Venkat Murli Krishna Vadlamani was appointed as Director on 15 Jul 2024. Zainul Fakhruddin Bharmal ceased to be Director on 08 Aug 2022. Murli Krishna Pharma has 15 board changes on record in total.

Yes, Murli Krishna Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0070963).

Murli Krishna Pharma has 5 MSME Form 1 returns on record between 2019 and 2023, listing 840 overdue payments to 26 micro and small suppliers. The latest return was filed on 29 Aug 2023.